Detection of AmpC beta-lactamase in Escherichia coli: Comparison of three phenotypic confirmation assays and genetic analysis

Journal of Clinical Microbiology

Volumn 49, Issue 8, 2011, Pages 2924-2932

  Peter Getzlaff, S ^a   Polsfuss, S ^a   Poledica, M ^a   Hombach, M ^a   Giger, J ^a   Bottger E C ^a   Zbinden, R ^a   Bloemberg, G V ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

AMPC GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISK DIFFUSION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENE MUTATION; GENETIC ANALYSIS; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PLASMIDS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

ESCHERICHIA COLI;

EID: 79960938559     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00091-11     Document Type: Article

References (40)

1. Bauernfeind, A., I. Schneider, R. Jungwirth, H. Sahly, and U. Ullmann. 1999. A novel type of AmpC beta lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob. Agents Chemother. 43:1924-1931.
2. Beesley, T., et al. 1983. The inhibition of class C β-lactamases by boronic acids. Biochem. J. 209:229-233. (Pubitemid 13153654)
3. Bell, J. M., et al. 2007. Prevalence and significance of a negative extended-spectrum β-lactamase (ESBL) confirmation test result after a positive ESBL test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J. Clin. Microbiol. 45:1478-1482.
4. Black, J. A., E. S. Moland, and K. S. Thomson. 2005. AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases. J. Clin. Microbiol. 43:3110-3113.
5. Bradford, P. A. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
6. Briñas, L., et al. 2005. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital. J. Antimicrob. Chemother. 56:1107-1110.
7. Caroff, N., E. Espaze, I. Bérard, H. Richet, and A. Reynaud. 1999. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyimino-cephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol. Lett. 173:459-465.
8. Caroff, N., E. Espaze, D. Gautreau, H. Richet, and A. Reynaud. 2000. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J. Antimicrob. Chemother. 45:783-788.
9. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Corvec, S., et al. 2007. Most Escherichia coli strains overproducing chromosomal AmpC beta-lactamase belong to phylogenetic group A. J. Antimicrob. Chemother. 60:872-876.
12. Dunne, W. M., Jr., and D. J. Hardin. 2005. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J. Clin. Microbiol. 43:5945-5949.
13. Forward, K. R., et al. 2001. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagn. Microbiol. Infect. Dis. 41:57-63.
14. Haldorsen, B., et al. 2008. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J. Antimicrob. Chemother. 62:694-702.
15. Honoré, N., M. H. Nicolas, and S. T. Cole. 1986. Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. EMBO J. 5:3709-3714.
16. Jacoby, G. A. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161-182.
17. Jaurin, B., T. Grundström, T. Edlund, and S. Normark. 1981. The E. coli β-lactamase attenuator mediates growth rate-dependent regulation. Nature 290:221-225. (Pubitemid 11149648)
18. Jørgensen, R. L., J. B. Nielsen, A. Friis-Møller, H. Fjeldsøe-Nielsen, and K. Schønning. 2010. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J. Antimicrob. Chemother. 65:460-464.
19. Mammeri, H., H. Guillon, F. Eb, and P. Nordmann. 2010. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC beta-lactamases. Antimicrob. Agents Chemother. 54:4556-4560.
20. Mammeri, H., F. Eb, A. Berkani, and P. Nordmann. 2008. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. J. Antimicrob. Chemother. 61:498-503.
21. Moland, E. S., et al. 2006. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J. Clin. Microbiol. 44:3318-3324. (Pubitemid 44413771)
22. Mulvey, M. R., et al. 2005. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother. 49:358-365.
23. Munier, G. K., et al. 2010. Positive extended-spectrum β-lactamase (ESBL) screening results may be due to AmpC β-lactamases more often than to ESBLs. J. Clin. Microbiol. 48:673-674.
24. Nelson, E. C., and B. G. Elisha. 1999. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 43:957-959.
25. Ohana, S., et al. 2005. Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC β-lactamase in a teaching hospital admitting disabled patients. Antimicrob. Agents Chemother. 49:2095-2097.
26. Oteo, J., et al. 2008. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int. J. Antimicrob. Agents 32:534-537.
27. Pai, H., et al. 2004. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:3720-3728.
28. Papagiannitsis, C. C., L. S. Tzouvelekis, E. Tzelepi, and V. Miriagou. 2007. Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. Antimicrob. Agents Chemother. 51:3763-3767.
29. Pérez-Pérez, F. J., and N. D. Hanson. 2002. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162.
30. Philippon, A., G. Arlet, and G. A. Jacoby. 2002. Plasmid-determined AmpC type β-lactamases. Antimicrob. Agents Chemother. 46:1-11.
31. Pitout, J. D., N. D. Hanson, D. L. Church, and K. B. Laupland. 2004. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin. Infect. Dis. 38:1736-1741.
32. Ruppé, E., P. Bidet, C. Verdet, G. Arlet, and E. Bingen. 2006. First detection of the Ambler class C 1 AmpC beta-lactamase in Citrobacter freundii by a new, simple double-disk synergy test. J. Clin. Microbiol. 44:4204-4207.
33. Schechner, V., et al. 2009. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J. Clin. Microbiol. 47:3261-3265.
34. Siu, L. K., P. L. Lu, J. Y. Chen, F. M. Lin, and S. C. Chang. 2003. High-level expression of ampC β-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment. Antimicrob. Agents Chemother. 47:2138-2144.
35. Sutton, L. D., D. J. Biedenbach, A. Yenn, and R. N. Jones. 1995. Development, characterization and initial evaluations of S1. A new chromogenic cephalosporin for β-lactamase detection. Diagn. Microbiol. Infect. Dis. 21:1-8.
36. Tan, T.Y., et al. 2009. Evaluation of screening methods to detect plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Antimicrob. Agents Chemother. 53:146-149.
37. Thomson, K. S. 2001. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg. Infect. Dis. 7:333-336.
38. Thomson, K. S. 2010. Extended-spectrum-β-lactamase, AmpC and carbapenemase issue. J. Clin. Microbiol. 48:1019-1025.
39. Tracz, D. M., et al. 2005. Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR. J. Antimicrob. Chemother. 55:758-772.
40. Tracz, D. M., et al. 2007. ampC gene expression in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates. FEMS Microbiol. Lett. 270:265-271.